全文获取类型
收费全文 | 4198篇 |
免费 | 356篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 138篇 |
妇产科学 | 96篇 |
基础医学 | 514篇 |
口腔科学 | 101篇 |
临床医学 | 542篇 |
内科学 | 696篇 |
皮肤病学 | 72篇 |
神经病学 | 616篇 |
特种医学 | 103篇 |
外科学 | 438篇 |
综合类 | 36篇 |
一般理论 | 12篇 |
预防医学 | 576篇 |
眼科学 | 41篇 |
药学 | 270篇 |
中国医学 | 5篇 |
肿瘤学 | 263篇 |
出版年
2024年 | 17篇 |
2023年 | 57篇 |
2022年 | 87篇 |
2021年 | 197篇 |
2020年 | 133篇 |
2019年 | 157篇 |
2018年 | 191篇 |
2017年 | 149篇 |
2016年 | 132篇 |
2015年 | 148篇 |
2014年 | 163篇 |
2013年 | 261篇 |
2012年 | 321篇 |
2011年 | 347篇 |
2010年 | 190篇 |
2009年 | 164篇 |
2008年 | 259篇 |
2007年 | 308篇 |
2006年 | 264篇 |
2005年 | 238篇 |
2004年 | 200篇 |
2003年 | 175篇 |
2002年 | 159篇 |
2001年 | 25篇 |
2000年 | 24篇 |
1999年 | 33篇 |
1998年 | 28篇 |
1997年 | 21篇 |
1996年 | 20篇 |
1995年 | 15篇 |
1994年 | 8篇 |
1993年 | 8篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 13篇 |
1989年 | 5篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有4564条查询结果,搜索用时 15 毫秒
31.
32.
Tanya M Tekautz Christine E Fuller Susan Blaney Maryam Fouladi Alberto Broniscer Thomas E Merchant Matthew Krasin James Dalton Gregory Hale Larry E Kun Dana Wallace Richard J Gilbertson Amar Gajjar 《Journal of clinical oncology》2005,23(7):1491-1499
PURPOSE: To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH). PATIENTS AND METHODS: Primary tumor samples from patients diagnosed with ATRT at SJCRH between July 1984 and June 2003 were identified. Pathology review included histologic, immunohistochemical analysis, and fluorescence in situ hybridization for SMARCB1 (also known as hSNF5/INI1) deletion. Clinical records of patients with pathologic confirmation of ATRT were reviewed. RESULTS: Thirty-seven patients were diagnosed with ATRT at SJCRH during the 19-year study interval. Six patients were excluded from this clinical review based on pathologic or clinical criteria. Of the remaining 31 patients, 22 were younger than 3 years. Posterior fossa primary lesions and metastatic disease at diagnosis were more common in younger patients with ATRT. All patients underwent surgical resection; 30 received subsequent chemotherapy. The majority of patients aged 3 years or older received postoperative craniospinal radiation. Two-year event-free (EFS) and overall survival (OS) of children aged 3 years or older (EFS, 78% + 14%; OS, 89% +/- 11%) were significantly better than those for younger patients (EFS, 11% +/- 6%; OS, 17% +/- 8%); EFS, P = .009 and OS, P = .0001. No other clinical characteristics were predictive of survival. Three of four patients 3 years or older with progressive disease were successfully rescued with ifosfamide, carboplatin, and etoposide therapy. CONCLUSION: Children presenting with ATRT before the age of 3 years have a dismal prognosis. ATRT presenting in older patients can be cured using a combination of radiation and high-dose alkylating therapy. Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy. 相似文献
33.
Tjede Funk Francesco Innocenti Joana Gomes Dias Lina Nerlander Tanya Melillo Charmaine Gauci Jackie M Melillo Patrik Lenz Helena Sebestova Pavel Slezak Iva Vlckova Jacob Dag Berild Camilla Mauroy Elina Seppl Ragnhild Tnnessen Anne Vergison Joël Mossong Silvana Masi Laetitia Huiart Gillian Cullen Niamh Murphy Lois OConnor Joan ODonnell Piers Mook Richard G Pebody Nick Bundle 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2022,27(35)
BackgroundUnderlying conditions are risk factors for severe COVID-19 outcomes but evidence is limited about how risks differ with age.AimWe sought to estimate age-specific associations between underlying conditions and hospitalisation, death and in-hospital death among COVID-19 cases.MethodsWe analysed case-based COVID-19 data submitted to The European Surveillance System between 2 June and 13 December 2020 by nine European countries. Eleven underlying conditions among cases with only one condition and the number of underlying conditions among multimorbid cases were used as exposures. Adjusted odds ratios (aOR) were estimated using 39 different age-adjusted and age-interaction multivariable logistic regression models, with marginal means from the latter used to estimate probabilities of severe outcome for each condition–age group combination.ResultsCancer, cardiac disorder, diabetes, immunodeficiency, kidney, liver and lung disease, neurological disorders and obesity were associated with elevated risk (aOR: 1.5–5.6) of hospitalisation and death, after controlling for age, sex, reporting period and country. As age increased, age-specific aOR were lower and predicted probabilities higher. However, for some conditions, predicted probabilities were at least as high in younger individuals with the condition as in older cases without it. In multimorbid patients, the aOR for severe disease increased with number of conditions for all outcomes and in all age groups.ConclusionWhile supporting age-based vaccine roll-out, our findings could inform a more nuanced, age- and condition-specific approach to vaccine prioritisation. This is relevant as countries consider vaccination of younger people, boosters and dosing intervals in response to vaccine escape variants. 相似文献
34.
Niven Mehra Karim Fizazi Johann S de Bono Philippe Barthlmy Tanya Dorff Adam Stirling Jean-Pascal Machiels Davide Bimbatti Deepak Kilari Herlinde Dumez Consuelo Buttigliero Inge M van Oort Elena Castro Hsiang-Chun Chen Nicola Di Santo Liza DeAnnuntis Cynthia G Healy Giorgio V Scagliotti 《The oncologist》2022,27(10):e783
BackgroundThe phase II TALAPRO-1 study () demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib.Patients and MethodsMen received talazoparib 1 mg/day (moderate renal impairment 0.75 mg/day) orally until radiographic progression, unacceptable toxicity, investigator decision, consent withdrawal, or death. Adverse events (AEs) were evaluated: incidence, severity, timing, duration, potential overlap of selected AEs, dose modifications/discontinuations due to AEs, and new clinically significant changes in laboratory values and vital signs.ResultsIn the safety population (N = 127; median age 69.0 years), 95.3% (121/127) experienced all-cause treatment-emergent adverse events (TEAEs). Most common were anemia (48.8% [62/127]), nausea (33.1% [42/127]), decreased appetite (28.3% [36/127]), and asthenia (23.6% [30/127]). Nonhematologic TEAEs were generally grades 1 and 2. No grade 5 TEAEs or deaths were treatment-related. Hematologic TEAEs typically occurred during the first 4-5 months of treatment. The median duration of grade 3-4 anemia, neutropenia, and thrombocytopenia was limited to 7-12 days. No grade 4 events of anemia or neutropenia occurred. Neither BRCA status nor alteration origin significantly impacted the safety profile. The median (range) treatment duration was 6.1 (0.4-24.9) months; treatment duration did not impact the incidence of anemia. Only 3 of the 15 (11.8% [15/127]) permanent treatment discontinuations were due to hematologic TEAEs (thrombocytopenia 1.6% [2/127]; leukopenia 0.8% [1/127]).ConclusionCommon TEAEs associated with talazoparib could be managed through dose modifications/supportive care. Demonstrated efficacy and a manageable safety profile support continued evaluation of talazoparib in mCRPC.ClinicalTrials.gov identifier NCT03148795 NCT03148795相似文献
35.
Laura A. Sena Rajendra Kumar David E. Sanin Elizabeth A. Thompson D. Marc Rosen Susan L. Dalrymple Lizamma Antony Yuhan Yang Carolina Gomes-Alexandre Jessica L. Hicks Tracy Jones Kiara A. Bowers Jillian N. Eskra Jennifer Meyers Anuj Gupta Alyza Skaist Srinivasan Yegnasubramanian Jun Luo W. Nathaniel Brennen Sushant K. Kachhap Emmanuel S. Antonarakis Angelo M. De Marzo John T. Isaacs Mark C. Markowski Samuel R. Denmeade 《The Journal of clinical investigation》2022,132(23)
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), termed bipolar androgen therapy (BAT), can result in tumor regression and clinical benefit for patients with castration-resistant prostate cancer. However, predictors and mechanisms of response and resistance have been ill defined. Here, we show that growth inhibition of prostate cancer models by SPA required high androgen receptor (AR) activity and were driven in part by downregulation of MYC. Using matched sequential patient biopsies, we show that high pretreatment AR activity predicted downregulation of MYC, improved clinical response, and prolonged progression-free and overall survival for patients on BAT. BAT induced strong downregulation of AR in all patients, which is shown to be a primary mechanism of acquired resistance to SPA. Acquired resistance was overcome by alternating SPA with the AR inhibitor enzalutamide, which induced adaptive upregulation of AR and resensitized prostate cancer to SPA. This work identifies high AR activity as a predictive biomarker of response to BAT and supports a treatment paradigm for prostate cancer involving alternating between AR inhibition and activation. 相似文献
36.
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) 下载免费PDF全文
37.
Portela JG Costa AC Teixeira LS 《Journal of pharmaceutical and biomedical analysis》2004,34(3):543-549
In this work, a new solid phase spectrophotometric method in association with flow injection analysis for Vitamin B6 (pyridoxine) determination has been developed with direct measurement of light-absorption in C18 material. In the developed method, successive passage of the complex, previously formed in the flowing stream, and eluent through the flow cell and continuous monitoring of the process provided the analytical information needed to determine pyridoxine. Pharmaceutical samples containing Vitamin B6 were previously dissolved in 0.1 mol l(-1) phosphate buffer solution (pH 7.5) and a sample volume of 235 microl was injected directly into carrier stream consisting of a mixture of methanol and 0.1 mol l(-1) phosphate buffer solution adjusted to pH 7.0 (1+1, v/v). The blue indophenol dye produced from the reaction between pyridoxine and N,N-diethyl-p-phenylenediamine after oxidation by potassium hexacyanoferrate(III) was quantitatively retained on C18 support and the spectrophotometric detection was performed simultaneously at 633 nm. The retained complex was quickly eluted from C18 material with the eluent stream consisting of a mixture of methanol and 0.01 mol l(-1) HCl (6+4, v/v). The results showed that the proposed method is simple, rapid and the analytical response is linear in the concentration range of 0.5-10 and 0.2-4 mg l(-1) using 235 and 860 microl of sample, respectively. The limits of detection are 0.15 and 0.060 mg l(-1) and the R.S.D. are 3.6% (at 2 mg l(-1) level) and 4.0% (at 1 mg l(-1) level) using sample volume of 235 and 860 microl, respectively. The system presented an analytical throughput of 15 determinations per hour when a sample volume of 235 microl was utilized. The procedure was successfully applied to the determination of Vitamin B6 in pharmaceutical formulations containing vitamins of B group and others active principles such as Vitamin C and minerals. 相似文献
38.
39.
40.